Above, diagram of the hypothesized role of MSCs to disrupt the cycle of neutrophil “NETosis” in COVID-19 lung damage, via its immunomodulatory paracrine activity on Tregs and macrophages. Could human ... More
On May 1st, thought leaders from the ISEV and ISCT published online in Cytotherapy a joint statement, “ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential ... More
Amid the global search for treatments for COVID-19 related lung disorders, MSCs emerged as one of the promising solutions to treat Acute Respiratory Distress Syndrome (ARDS) [1, 2]. (See our ... More
Authored by Mayasari Lim, PhD, Jonathan Carson, PhD, and Jon A. Rowley, PhD, RoosterBio, Inc. Some research suggests that ARDS might be treatable with the secretome of MSCs. Scientists and ... More
Scalability of EV Manufacturing is a Major Challenge Previously, we discussed the emergence of MSC extracellular vesicles (EVs) as clinical therapies. However, a critical barrier in the development of MSC-EVs as a ... More
MSC-EVs Emerge as a Cell-Free Therapy Extracellular vesicle (EV) interest continues to increase as more evidence emerges about the ability of these lipid-bilayer membrane vesicles to elicit specific responses from ... More